Daniel Schaid

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Use of parents, sibs, and unrelated controls for detection of associations between genetic markers and disease
    D J Schaid
    Departments of Health Sciences Research and Medical Genetics, Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
    Am J Hum Genet 63:1492-506. 1998
  2. ncbi Model-free sib-pair linkage analysis: combining full-sib and half-sib pairs
    D J Schaid
    Section of Biostatistics, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Genet Epidemiol 19:30-51. 2000
  3. ncbi Genetic epidemiology and haplotypes
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Genet Epidemiol 27:317-20. 2004
  4. ncbi Power and sample size for testing associations of haplotypes with complex traits
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Hum Genet 70:116-30. 2006
  5. ncbi A comprehensive examination of CYP19 variation and breast density
    Janet E Olson
    Division of Epidemiology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55901, USA
    Cancer Epidemiol Biomarkers Prev 16:623-5. 2007
  6. ncbi Regression modeling of allele frequencies and testing Hardy Weinberg Equilibrium
    Daniel J Schaid
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Hum Hered 74:71-82. 2012
  7. ncbi Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies
    Daniel J Schaid
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
    Genet Epidemiol 37:229-38. 2013
  8. ncbi Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies
    Daniel J Schaid
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Genet Epidemiol 36:3-16. 2012
  9. ncbi Application of sequential haplotype scan methods to case-control data
    Zhaoxia Yu
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Harwick 7, 200 First Street Southwest, Rochester, Minnesota 55905, USA
    BMC Proc 1:S21. 2007
  10. ncbi Identifying single-nucleotide polymorphisms responsible for the linkage signal of rheumatoid arthritis on chromosome 6 by joint modeling of linkage and association
    Wan Yu Lin
    Institute of Epidemiology, National Taiwan University, Floor 5, NO, 17, Shiujou Road, Zhongzheng District, Taipei 100, Taiwan
    BMC Proc 1:S40. 2007

Research Grants

  1. Quantitative Methods for Genetic Epidemiology
    Daniel Schaid; Fiscal Year: 2005
  2. Quantitative Methods for Genetic Epidemiology
    Daniel Schaid; Fiscal Year: 2009
  3. Quantitative Methods for Genetic Epidemiology
    Daniel Schaid; Fiscal Year: 2007
  4. Quantitative methods for genetic linkage heterogeneity
    Daniel Schaid; Fiscal Year: 2007
  5. QUANTITATIVE ASSOCIATION METHODS FOR GENE MAPPING
    Daniel Schaid; Fiscal Year: 2001

Detail Information

Publications90

  1. ncbi Use of parents, sibs, and unrelated controls for detection of associations between genetic markers and disease
    D J Schaid
    Departments of Health Sciences Research and Medical Genetics, Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
    Am J Hum Genet 63:1492-506. 1998
    ..The results presented will be useful for investigators planning studies using sibs as controls...
  2. ncbi Model-free sib-pair linkage analysis: combining full-sib and half-sib pairs
    D J Schaid
    Section of Biostatistics, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Genet Epidemiol 19:30-51. 2000
    ..The main appeal of our proposed method is the speed at which it can be computed, offering a rapid way to perform genome-wide linkage screens...
  3. ncbi Genetic epidemiology and haplotypes
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Genet Epidemiol 27:317-20. 2004
  4. ncbi Power and sample size for testing associations of haplotypes with complex traits
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Hum Genet 70:116-30. 2006
    ..Simulations illustrate that the theoretical power predictions are quite accurate over a broad range of conditions. Our theoretical formulae should provide useful guidance when planning haplotype association studies...
  5. ncbi A comprehensive examination of CYP19 variation and breast density
    Janet E Olson
    Division of Epidemiology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55901, USA
    Cancer Epidemiol Biomarkers Prev 16:623-5. 2007
  6. ncbi Regression modeling of allele frequencies and testing Hardy Weinberg Equilibrium
    Daniel J Schaid
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Hum Hered 74:71-82. 2012
    ..To date, all methods testing for HWE require subjects to be classified into discrete categories, yet it is becoming clear that the distribution of allele frequencies tends to be smooth over geographic regions...
  7. ncbi Two-phase designs to follow-up genome-wide association signals with DNA resequencing studies
    Daniel J Schaid
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
    Genet Epidemiol 37:229-38. 2013
    ..Hence, the two-phase design provides an efficient approach to follow-up GWAS signals with DNA resequencing...
  8. ncbi Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies
    Daniel J Schaid
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Genet Epidemiol 36:3-16. 2012
    ..Application of our methods to two different GWAS provide guidance on the potential strengths and weaknesses of our proposed gene-set analyses...
  9. ncbi Application of sequential haplotype scan methods to case-control data
    Zhaoxia Yu
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Harwick 7, 200 First Street Southwest, Rochester, Minnesota 55905, USA
    BMC Proc 1:S21. 2007
    ..The results showed that our new approach is at least as powerful as the traditional single-locus analysis and sometimes can be more powerful...
  10. ncbi Identifying single-nucleotide polymorphisms responsible for the linkage signal of rheumatoid arthritis on chromosome 6 by joint modeling of linkage and association
    Wan Yu Lin
    Institute of Epidemiology, National Taiwan University, Floor 5, NO, 17, Shiujou Road, Zhongzheng District, Taipei 100, Taiwan
    BMC Proc 1:S40. 2007
    ....
  11. ncbi Genotype determination for polymorphisms in linkage disequilibrium
    Zhaoxia Yu
    Department of Statistics, University of California, Irvine, CA, USA
    BMC Bioinformatics 10:63. 2009
    ..Although many statistical methods have been developed to improve either genotype calling or imputation of missing genotypes, treating the two steps independently can lead to loss of genetic information...
  12. ncbi Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics
    Daniel J Schaid
    Harwick 7, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hum Genet 120:471-85. 2006
    ..This provides a basis for attempts to identify these genes, with potential clinical utility for men with aggressive prostate cancer and their relatives...
  13. ncbi One- and two-locus models for mapping rheumatoid arthritis-susceptibility genes on chromosome 6
    Daniel J Schaid
    Division of Biostatistics, Harwick 7, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905, USA
    BMC Proc 1:S103. 2007
    ..7-69.6 cM, providing evidence for a second rheumatoid arthritis susceptibility locus on chromosome 6...
  14. ncbi The complex genetic epidemiology of prostate cancer
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    Hum Mol Genet 13:R103-21. 2004
    ....
  15. ncbi Regression models for linkage: issues of traits, covariates, heterogeneity, and interaction
    Daniel J Schaid
    Department of Health Sciences Research, Division of Biostatistics, Mayo Clinic Foundation, Rochester, Minn 55905, USA
    Hum Hered 55:86-96. 2003
    ..The purposes of this paper are to review some recent developments in the linkage regression framework, to emphasize strengths and weaknesses of various proposed methods, and to highlight some important assumptions and caveats...
  16. ncbi Linkage disequilibrium testing when linkage phase is unknown
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Genetics 166:505-12. 2004
    ..We extend the composite statistic to allow for more than two alleles per locus, providing a global composite statistic, which is a strong competitor to the usual likelihood-ratio statistic...
  17. ncbi Testing genetic linkage with relative pairs and covariates by quasi-likelihood score statistics
    Daniel J Schaid
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hum Hered 64:220-33. 2007
    ....
  18. ncbi Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Hum Genet 75:948-65. 2004
    ..The strengths and weaknesses of microsatellite versus SNP markers are illustrated by the results of our genome linkage scans...
  19. ncbi Evaluating associations of haplotypes with traits
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Genet Epidemiol 27:348-64. 2004
    ..Future work that links regression methods with population genetic models may prove beneficial...
  20. ncbi Robust multipoint identical-by-descent mapping for affected relative pairs
    Daniel J Schaid
    Department of Health Sciences Research, Harwick 7, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hum Genet 76:128-38. 2005
    ..To evaluate the adequacy of the constrained model, we developed a robust score statistic. These methods are applied to a prostate cancer-linkage study, which emphasizes their potential advantages and limitations...
  21. ncbi Affected relative pairs and simultaneous search for two-locus linkage in the presence of epistasis
    Daniel J Schaid
    Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Genet Epidemiol 31:431-49. 2007
    ..These novel score statistics should prove useful for linkage studies of other complex human diseases...
  22. ncbi Nonparametric tests of association of multiple genes with human disease
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hum Genet 76:780-93. 2005
    ..Application of our methods to a study of candidate genes for prostate cancer illustrates their potential merits, and offers guidelines for interpretation...
  23. ncbi Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata
    Daniel J Schaid
    Section of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hum Genet 79:1071-80. 2006
    ..Hence, our new methods should be useful for samples composed of multiple ethnic groups...
  24. ncbi Case-parents design for gene-environment interaction
    D J Schaid
    Department of Health Sciences Research, Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
    Genet Epidemiol 16:261-73. 1999
    ....
  25. ncbi Likelihoods and TDT for the case-parents design
    D J Schaid
    Department of Health Sciences Research, Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
    Genet Epidemiol 16:250-60. 1999
    ..Finally, we discuss how to use standard software for conditional logistic regression to accurately assess effects of alleles as well as genotype-environment interaction...
  26. ncbi Evidence for autosomal dominant inheritance of prostate cancer
    D J Schaid
    Department of Health Sciences Research, Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
    Am J Hum Genet 62:1425-38. 1998
    ....
  27. ncbi Robust transmission regression models for linkage and association
    D J Schaid
    Department of Health Sciences Research, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Genet Epidemiol 19:S78-84. 2000
    ..The basic features of the regression model are presented, as well as discussions of potential applications and critical statistical issues...
  28. ncbi Regression models for linkage heterogeneity applied to familial prostate cancer
    D J Schaid
    Departments of Health Sciences Research and Medical Genetics, Mayo Clinic Foundation, Rochester, MN, 55905, USA
    Am J Hum Genet 68:1189-96. 2001
    ..This new regression method is applied to linkage data for familial prostate cancer and provides new insights into the understanding of prostate cancer linkage heterogeneity...
  29. ncbi Estimation of genotype relative risks from pedigree data by retrospective likelihoods
    Daniel J Schaid
    Division of Biomedical Statistics and Informatics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Genet Epidemiol 34:287-98. 2010
    ..When modeling only the affected family members in our data, there was little evidence for heterogeneity in baseline risks across families...
  30. ncbi Score tests for association between traits and haplotypes when linkage phase is ambiguous
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic Foundation, Rochester, MN 55905, USA
    Am J Hum Genet 70:425-34. 2002
    ..Limited simulations are also presented to demonstrate the validity of our methods, as well as to provide guidelines on how our methods could be used...
  31. ncbi Two-stage case-control designs for rare genetic variants
    Daniel J Schaid
    Division of Biomedical Statistics and Informatics, Harwick 7, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Hum Genet 127:659-68. 2010
    ....
  32. ncbi Searching for epistasis and linkage heterogeneity by correlations of pedigree-specific linkage scores
    Daniel J Schaid
    Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Genet Epidemiol 32:464-75. 2008
    ....
  33. ncbi Relative efficiency of ambiguous vs. directly measured haplotype frequencies
    Daniel J Schaid
    Departments of Health Sciences Research and Medical Genetics, Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Genet Epidemiol 23:426-43. 2002
    ..Genet. Epidemiol. 23:426-443, 2002...
  34. ncbi Genetic epidemiology and microarrays
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA
    Genet Epidemiol 23:1-3. 2002
  35. ncbi Sequential haplotype scan methods for association analysis
    Zhaoxia Yu
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Genet Epidemiol 31:553-64. 2007
    ..As a result, our methods can achieve greater power than the single-locus method, yet is much more computationally efficient than sliding window methods...
  36. ncbi Methylenetetrahydrofolate reductase haplotype tag single-nucleotide polymorphisms and risk of breast cancer
    Yvette N Martin
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 15:2322-4. 2006
  37. ncbi Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics
    Yvette N Martin
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Pharmacogenet Genomics 16:265-77. 2006
    ..These observations represent steps towards an understanding of molecular genetic mechanisms responsible for variation in MTHFR function that may contribute to individual differences in drug efficacy and toxicity, as well as disease risk...
  38. ncbi Complex segregation analysis of Parkinson's disease: The Mayo Clinic Family Study
    Shannon K McDonnell
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 59:788-95. 2006
    ..The best fitting models for older onset PD (age > 59 years) were a recessive or an additive model. INTERPRETATION: The familial aggregation of PD may be explained in part by a major gene with additive effect on the penetrance...
  39. ncbi Polymorphisms in mitochondrial genes and prostate cancer risk
    Liang Wang
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 17:3558-66. 2008
    ..Overall, these results suggest that polymorphisms in the mitochondrial genome and those in the nuclear-encoded mitochondrial genes evaluated are not substantial risk factors for prostate cancer...
  40. ncbi Human aromatase: gene resequencing and functional genomics
    Cynthia X Ma
    Department of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 65:11071-82. 2005
    ..These observations indicate that genetic variation in CYP19 might contribute to variation in the pathophysiology of estrogen-dependent disease...
  41. ncbi Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics
    Yuan Ji
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Pharmacol Exp Ther 322:529-40. 2007
    ..These studies resulted in the identification of common SULT2B1 gene sequence variation, as well as insight into the effects of that variation on the function of this important steroid-metabolizing enzyme...
  42. ncbi Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13
    Daniel J Schaid
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Prostate 63:276-90. 2005
    ..This study illustrates the value of the ICPCG family collection to evaluate reported linkage signals and suggests that the HPC20 region does not make a major contribution to PC susceptibility...
  43. ncbi Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies
    Thomas C Wood
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Biol Chem 281:7364-73. 2006
    ..These results raise the possibility that inherited variation in AS3MT may contribute to variation in arsenic metabolism and, perhaps, arsenic-dependent carcinogenesis in humans...
  44. ncbi Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms
    Yuan Ji
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 68:5997-6005. 2008
    ....
  45. ncbi Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study
    Julie M Cunningham
    Department of Laboratory Medicine and Pathology, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA
    Prostate 57:335-46. 2003
    ..However, chromosomes 6 and X showed suggestive results, with maximum LOD - ZLR values of 1.38 and 1.36, respectively. Subset analyses suggest additional chromosomal regions worth further follow-up...
  46. ncbi Glutathione S-transferase omega 1 and omega 2 pharmacogenomics
    Baidehi Mukherjee
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Drug Metab Dispos 34:1237-46. 2006
    ..These observations raise the possibility of functionally significant pharmacogenomic variation in the expression and function of GSTO1 and GSTO2...
  47. ncbi Human phenylethanolamine N-methyltransferase genetic polymorphisms and exercise-induced epinephrine release
    Yuan Ji
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Foundation, Rochester, Minnesota 55905, USA
    Physiol Genomics 33:323-32. 2008
    ..Our studies suggest that functionally significant variant sequence in the human PNMT gene might contribute to individual variation in levels of circulating epinephrine during exercise...
  48. ncbi Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics
    Ann M Moyer
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:7207-16. 2007
    ..We set out to systematically identify common polymorphisms in GSTT1 and GSTM1, followed by functional genomic studies...
  49. ncbi Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer
    Jose D Debes
    Department of Urology, Mayo Clinic College of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 155:82-6. 2004
    ..84 (0.65-1.09), P=0.37]. These data indicate that there is no associated risk for sporadic or familial PCa in American families containing the GSTP1 I105V polymorphism...
  50. ncbi Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies
    Jianping Zhang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 19:577-87. 2009
    ..We set out to test the hypothesis that additional COMT polymorphisms might also be associated with phenotypic variation...
  51. ncbi Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer
    Julie M Cunningham
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 16:969-78. 2007
    ..Given that the point estimates for the odds ratio for each of these polymorphisms are <2.0, much larger sample sizes will be required for confirmation...
  52. ncbi Human glucocorticoid receptor alpha gene (NR3C1) pharmacogenomics: gene resequencing and functional genomics
    Nifang Niu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Endocrinol Metab 94:3072-84. 2009
    ..There are large variations in both physiological and therapeutic response to glucocorticoids. Multiple previous studies suggested that genetic polymorphisms in GRalpha (NR3C1) might play an important role...
  53. ncbi Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics
    Ryan Abo
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    Pharmacogenet Genomics 22:247-53. 2012
    ....
  54. ncbi Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease
    Walter A Rocca
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Arch Neurol 64:1458-64. 2007
    ..The evidence for increased risk of dementia in relatives of patients with Parkinson disease (PD) remains conflicting...
  55. ncbi Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
    James N Ingle
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:4674-82. 2010
    ....
  56. ncbi Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine
    Jennifer L St Sauver
    Section of Clinical Epidemiology, Department of Health Sciences Research, Vaccine Research Group, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    J Infect Dis 185:1545-9. 2002
    ..These results suggest that lack of HLA diversity may limit the range of peptides that can be presented to antibody-producing cells, potentially resulting in a decreased immune response to viral infections...
  57. ncbi Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer
    Scott J Hebbring
    Mayo Clinic Rochester, 200 First Street Southwest, 920 Hilton Building, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 15:935-8. 2006
    ..However, our data does suggest that mutations within NBS1, and in particular, 657del5, do not significantly contribute to the overall prostate cancer burden within our patient samples...
  58. ncbi Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease
    Demetrius M Maraganore
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mov Disord 17:509-12. 2002
    ..While exogenous and endogenous estrogen may modify the risk of PD in women, the two estrogen receptor gene polymorphisms considered here do not seem to contribute to PD susceptibility...
  59. ncbi Associations between measles antibody levels and the protein structure of class II human leukocyte antigens
    Jennifer L St Sauver
    Department of Health Sciences Research, Mayo Clinic and Foundation, Mayo Vaccine Research Group, Rochester, MN 55905, USA
    Hum Immunol 64:696-707. 2003
    ..Our data suggest that specific DQA and DQB amino acid variations are associated with measles seronegativity after vaccination...
  60. ncbi Glutathione s-transferase p1: gene sequence variation and functional genomic studies
    Ann M Moyer
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School Mayo Clinic, Rochester, Minnesota, USA
    Cancer Res 68:4791-801. 2008
    ....
  61. ncbi The association of class I HLA alleles and antibody levels after a single dose of measles vaccine
    Robert M Jacobson
    Department of Pediatric and Adolescent MedicineMayo Clinic, Rochester, MN 55903, USA
    Hum Immunol 64:103-9. 2003
    ....
  62. ncbi Mutations in CHEK2 associated with prostate cancer risk
    Xiangyang Dong
    Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic Mayo Medical School, Rochester, MN 55905, USA
    Am J Hum Genet 72:270-80. 2003
    ..Overall, our data suggest that mutations in CHEK2 may contribute to prostate cancer risk and that the DNA-damage-signaling pathway may play an important role in the development of prostate cancer...
  63. ncbi Strong evidence of a genetic determinant for mammographic density, a major risk factor for breast cancer
    Celine M Vachon
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Res 67:8412-8. 2007
    ..4 cM). The putative locus on chromosome 5p is likely to account for up to 22% of variation in MD. Hence, 1 or more of the 45 candidate genes in this region could explain a large proportion of MD and, potentially, breast cancer...
  64. ncbi Familial aggregation of Parkinson's disease: The Mayo Clinic family study
    Walter A Rocca
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 56:495-502. 2004
    ..62; 95% confidence interval, 1.66-4.15), whereas relatives of probands with later onset had no increased risk. The relative risk decreased when the incidence of all types of parkinsonism was considered...
  65. ncbi A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches
    Janet E Olson
    Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Breast Cancer Res Treat 102:237-47. 2007
    ..We recently published resequencing data on 88 polymorphisms identified in that gene. The hypothesis tested in this study was that polymorphisms, or haplotypes, in CYP19 are related to risk of breast cancer...
  66. ncbi The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis
    Carl Turesson
    Department of Rheumatology, Malmo University Hospital, Södra Förstadsgatan 101, 205 02 Malmo, Sweden
    Arthritis Res Ther 7:R1386-93. 2005
    ..This confirms that SE genes contribute to RA disease severity and ExRA. Other genetic and environmental factors may have a more specific impact on individual ExRA manifestations...
  67. ncbi A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity
    Brooke L Fridley
    Department of Health Sciences Research, Harwick 766, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Stat Med 28:2709-22. 2009
    ....
  68. ncbi Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer
    James N Ingle
    Division of Medical Oncology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:3278-86. 2010
    ..These findings may have implications with regard to efficacy and adverse events and may indicate the need to "individualize" therapy with this drug...
  69. ncbi Two common chromosome 8q24 variants are associated with increased risk for prostate cancer
    Liang Wang
    Departments of Laboratory Medicine and Pathology, Health Sciences Research, and Urology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Cancer Res 67:2944-50. 2007
    ..00005). These results further confirm the importance of these two polymorphic variants (rs1447295 and DG8S737) as risk factors for PC. However, the mechanism explaining this increased risk has not yet been established...
  70. ncbi Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis
    Carl Turesson
    Department of Rheumatology, Malmo University Hospital, Malmo, Sweden
    Arthritis Rheum 54:2776-83. 2006
    ..To compare HLA-C genotypes and smoking habits in patients with vasculitis or other severe extraarticular manifestations of rheumatoid arthritis (ExRA) with those in RA patients without extraarticular disease...
  71. ncbi Increased risk of essential tremor in first-degree relatives of patients with Parkinson's disease
    Walter A Rocca
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mov Disord 22:1607-14. 2007
    ..These findings suggest that PD and ET may share familial susceptibility factors...
  72. ncbi Analysis of the RNASEL gene in familial and sporadic prostate cancer
    Liang Wang
    Department of Laboratory Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Am J Hum Genet 71:116-23. 2002
    ..82; P=.03), as well as in the subset analyses. These results suggest that polymorphic changes within the RNASEL gene may be associated with increased risk of familial but not sporadic PC...
  73. ncbi Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q
    Daniel J Schaid
    Division of Biostatistics, Mayo Clinic, Rochester, MN, USA
    Hum Genet 121:729-35. 2007
    ..001) was found on chromosomes 19q and 5q, with P-values <or= 0.01 observed on chromosomes 3q, 7q, and 16q. Our results confirm reports of Gleason score linkage to chromosome 19q and suggest new loci for further investigation...
  74. ncbi The Mayo Clinic family study of Parkinson's disease: study design, instruments, and sample characteristics
    Walter A Rocca
    Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minn, USA
    Neuroepidemiology 24:151-67. 2005
    ..Finally, we studied a group of 625 spouses of either cases or controls. Relatives with PD or other neurodegenerative diseases were ascertained using the family study method...
  75. ncbi Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression
    Liang Li
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 68:7050-8. 2008
    ..Our results suggest that cell-based model system studies, when combined with complementary functional characterization, may help to identify biomarkers for response to chemotherapy with these cytidine analogues...
  76. ncbi Risk tables for parkinsonism and Parkinson's disease
    Alexis Elbaz
    Department of Health Sciences Research, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Epidemiol 55:25-31. 2002
    ..Lifetime risk estimates are useful in clinical practice, epidemiologic research, and public health...
  77. ncbi Conference Scene: Lessons learned from the 5th Statistical Analysis Workshop of the Pharmacogenetics Research Network
    Elizabeth J Atkinson
    Division of Biomedical Statistics and Informatics, Mayo Clinic, MN, USA
    Pharmacogenomics 11:297-303. 2010
    ..Overall, the workshop emphasized the need for diverse approaches to conducting pharmacogenomics studies, as well as the evolving nature of the field...
  78. ncbi Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers
    Camilo Adem
    Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 97:1-11. 2003
    ..This increased progression rate should be taken into account when considering the surveillance of asymptomatic women...
  79. ncbi Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: common gene sequence variation and functional characterization
    Fang Li
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mol Genet Metab 94:326-35. 2008
    ..These studies have defined common genetic variation in BHMT and BHMT2 and functionally characterized BHMT SNPs. They may also help to explain why BHMT2 has not previously been defined functionally...
  80. ncbi TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors
    Colleen S Sinclair
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 62:3587-91. 2002
    ..TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors...
  81. ncbi Caution on pedigree haplotype inference with software that assumes linkage equilibrium
    Daniel J Schaid
    Am J Hum Genet 71:992-5. 2002
  82. ncbi Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24
    Miia Suuriniemi
    Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA
    Cancer Epidemiol Biomarkers Prev 16:809-14. 2007
    ..S. samples. Although the data were provocative, the U.S. samples were not population based, which precludes assessment of the potential contribution of this locus to prostate cancer incidence in the United States...
  83. ncbi Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics
    Nicola J Camp
    University of Utah ICPCG Group and Division of Genetic Epidemiology, University of Utah School of Medicine, 391 Chipeta Way, Suite D, Salt Lake City, UT 84108, USA
    Hum Mol Genet 16:1271-8. 2007
    ..This collaborative study by the ICPCG illustrates the value of consortium efforts and the continued utility of linkage analysis using informative pedigrees to localize genes for complex diseases...
  84. ncbi A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics
    Jianfeng Xu
    Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA
    Am J Hum Genet 77:219-29. 2005
    ....
  85. ncbi Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb
    Bo Johanneson
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
    Hum Genet 123:65-75. 2008
    ..Combining these results with data from the earlier ICPCG study reduces the three-recombination interval at 22q12.3 to approximately 1.36 Mb...
  86. ncbi Robust multipoint simultaneous identical-by-descent mapping for two linked loci
    Wan Yu Lin
    Institute of Epidemiology, National Taiwan University, Taipei, Taiwan
    Hum Hered 63:35-46. 2007
    ..We have implemented the multipoint IBD mapping for one and two linked loci in our software GEEARP, which allows analyses for five general types of ARPs...
  87. ncbi Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer
    Julius Gudmundsson
    deCODE Genetics, 101 Reykjavik, Iceland
    Nat Genet 40:281-3. 2008
    ..23 and 1.15; P = 3.9 x 10(-13) and 7.7 x 10(-9), respectively). The 2p15 variant shows a significantly stronger association with more aggressive, rather than less aggressive, forms of the disease...
  88. ncbi Where are the prostate cancer genes?--A summary of eight genome wide searches
    Douglas F Easton
    Cancer Research U K Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, United Kingdom
    Prostate 57:261-9. 2003
    ..There is strong evidence for genetic susceptibility to prostate cancer, but most of the genes underlying this susceptibility remain to be identified...
  89. ncbi Methods to impute missing genotypes for population data
    Zhaoxia Yu
    Department of Statistics, University of California, Irvine, CA 92697, USA
    Hum Genet 122:495-504. 2007
    ..LM.lars gives slightly less accurate estimate of missing genotypes than fastPHASE, but has better performance than the other methods...
  90. ncbi Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness
    Janet L Stanford
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, and Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington 98109 1024, USA
    Prostate 66:317-25. 2006
    ..Linkage studies attempting to map genes for hereditary prostate cancer (HPC) have proved challenging, and one potential problem contributing to this challenge is the variability in disease phenotypes...

Research Grants15

  1. Quantitative Methods for Genetic Epidemiology
    Daniel Schaid; Fiscal Year: 2005
    ..Aim 4. Develop user-friendly software that implements our methods and make them widely available to biomedical researchers, including well-documented procedures and examples on their usage. ..
  2. Quantitative Methods for Genetic Epidemiology
    Daniel Schaid; Fiscal Year: 2009
    ..Through development of new quantitative methods, our research has the potential to improve the diagnosis, prognosis, and treatment of complex genetic human diseases, as well as other human traits. ..
  3. Quantitative Methods for Genetic Epidemiology
    Daniel Schaid; Fiscal Year: 2007
    ..Through development of new quantitative methods, our research has the potential to improve the diagnosis, prognosis, and treatment of complex genetic human diseases, as well as other human traits. ..
  4. Quantitative methods for genetic linkage heterogeneity
    Daniel Schaid; Fiscal Year: 2007
    ..Aim 3. User-friendly software: User-friendly software that implements the proposed methods, including well-documented procedures and examples of their usage, will be provided free to the scientific community. ..
  5. QUANTITATIVE ASSOCIATION METHODS FOR GENE MAPPING
    Daniel Schaid; Fiscal Year: 2001
    ..The advantages of this proposed research, over those currently used to identify and characterize genes of complex diseases, are that it will offer a more powerful and flexible method to find these types of genes. ..